News

10
Jun

Injection site reactions platform

ISR PlatformA PROPRIETARY PLATFORM TO TEST INJECTION SITE REACTIONS IN HUMANS AHEAD OF CLINICAL TRIAL.A NEW PROPRIETARY RESEARCH TOOL TO IDENTIFY MAST CELLS-DEPENDENT & INDEPENDENT INJECTION SITE REACTIONS IN HUMAN SKIN. Today, biologics represent one of the fastest growing markets within the pharmaceutical industry. The pipeline of biological drugs is growing at a rapid pace with a global market expected
Read more
9
Jun

Interview with Pr. Guy Serre

10 Year Anniversary: Interview with Pr. Guy Serre For our 10th anniversary, we spoke to people who helped Genoskin become what it is today. Back in March, we had a chat with Pr. Guy Serre, Director of the UDEAR lab (Epidermis Differentiation and Rheumatoid Autoimmunity Unit), the place where Genoskin was born. Genoskin: Could you describe the relationship between your
Read more
22
Feb

Using NativeSkin® to study poison ivy-induced dermatitis

Using NativeSkin® to evaluate poison ivy effects  A couple of months ago, Genoskin’s team started to wonder: “Why not try to better understand poison ivy dermatitis through our NativeSkin® model ?” In this article, we summarize information about what is known regarding the poison ivy reaction and what happens on a macroscopic level when poison ivy toxin is applied to
Read more
30
Nov

Human connective tissue mast cells

Human connective tissue mast cells A cellular model to better understand the underlying mechanisms of Injection Site Reactions (ISRs) and other severe allergic reactions. Mast cell culture assays are critical to better understand the kinetics and dynamics underlying inflammatory reactions. Genoskin’s team of experts has developed a method to grow connective tissue-type mast cells (CTMCs) derived from the peripheral blood
Read more
20
Nov

Top things found in human skin!

Top things found in human skin (vs in reconstructed human skin models) Skin is our largest organ (2m2). Since the skin is a mandatory test organ for regulatory agencies, every single drug in development needs to be tested for potential skin toxicity. Today, efficacy and safety studies are performed either on animal skin, reconstructed skin, or ex vivo human skin.
Read more
28
Oct

A unique ex vivo perfused human skin model to test pharmacokinetic and systemic administration in human skin

The FlowSkin® platform : a unique ex vivo perfused human skin model to test pharmacokinetic and systemic administration in human skin When human tissue culture meets microfluidic technology, it leads to the first perfused human skin model ; an amazing platform to overcome the challenges of drug development and replace animal testing. Almost 10 years ago now, Genoskin developed the
Read more